Advanced search
1 file | 88.57 KB Add to list

Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with Infliximab

Author
Organization
Abstract
Objective. Anemia is a common complication in patients with inflammatory diseases such as ankylosing spondylitis (AS). This post hoc analysis of a large, randomized, placebo-controlled trial examined the effect of infliximab on hemoglobin levels, physical function, and fatigue in patients with AS. Methods. Patients received infliximab 5 mg/kg (n = 188) or placebo (n = 68) at weeks 0, 2, 6, 12, and 18. Hemoglobin, interleukin-6 (IL-6), and C-reactive protein (CRP) levels, fatigue (visual analog scale [VAS]), physical function (Bath Ankylosing Spondylitis Functional Index [BASFI]) and disease activity were evaluated at baseline and week 24. Anemia was defined as a hemoglobin level <12 gm/dl for women and <13 gm/dl for men. Results. At baseline, 11 placebo group patients (16.2%) and 37 infliximab group patients (19.7%) had anemia. Of these, more infliximab-treated patients achieved normal hemoglobin levels at week 24 compared with patients receiving placebo (70.3% versus 27.3%; P = 0.0155). Infliximab-treated patients had significant improvements in mean hemoglobin concentration (0.7 gm/dl versus -0.3 gm/dl), BASFI score (-2.1 versus -0.2), and fatigue VAS score (-2.4 versus -0.4) compared with placebo patients (P < 0.001). Multiple regression analyses showed that improvements in hemoglobin level were significantly and independently associated with improvements in physical function and fatigue. Infliximab-treated patients with elevated CRP or IL-6 levels at baseline were more likely than those with low levels to have improvement in hemoglobin levels. Conclusion. Infliximab treatment significantly decreased the proportion of AS patients with anemia and improved hemoglobin levels compared with placebo. Improvement in hemoglobin level was independently associated with improvements in physical function and fatigue.

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 88.57 KB

Citation

Please use this url to cite or link to this publication:

MLA
Braun, Juergen et al. “Improvement in Hemoglobin Levels in Patients with Ankylosing Spondylitis Treated with Infliximab.” ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH 61.8 (2009): 1032–1036. Print.
APA
Braun, J., van der Heijde, D., Doyle, M., Han, C., Deodhar, A., Inman, R., de Vlam, K., et al. (2009). Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with Infliximab. ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 61(8), 1032–1036.
Chicago author-date
Braun, Juergen, Desiree van der Heijde, Mittie Doyle, Chenglong Han, Atul Deodhar, Robert Inman, Kurt de Vlam, et al. 2009. “Improvement in Hemoglobin Levels in Patients with Ankylosing Spondylitis Treated with Infliximab.” Arthritis & Rheumatism-arthritis Care & Research 61 (8): 1032–1036.
Chicago author-date (all authors)
Braun, Juergen, Desiree van der Heijde, Mittie Doyle, Chenglong Han, Atul Deodhar, Robert Inman, Kurt de Vlam, Gerd Burmester, Filip Van den Bosch, Stephen Xu, Sudha Visvanathan, and Mahboob Rahman. 2009. “Improvement in Hemoglobin Levels in Patients with Ankylosing Spondylitis Treated with Infliximab.” Arthritis & Rheumatism-arthritis Care & Research 61 (8): 1032–1036.
Vancouver
1.
Braun J, van der Heijde D, Doyle M, Han C, Deodhar A, Inman R, et al. Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with Infliximab. ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH. Wiley-Liss; 2009;61(8):1032–6.
IEEE
[1]
J. Braun et al., “Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with Infliximab,” ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, vol. 61, no. 8, pp. 1032–1036, 2009.
@article{845856,
  abstract     = {Objective. Anemia is a common complication in patients with inflammatory diseases such as ankylosing spondylitis (AS). This post hoc analysis of a large, randomized, placebo-controlled trial examined the effect of infliximab on hemoglobin levels, physical function, and fatigue in patients with AS.

Methods. Patients received infliximab 5 mg/kg (n = 188) or placebo (n = 68) at weeks 0, 2, 6, 12, and 18. Hemoglobin, interleukin-6 (IL-6), and C-reactive protein (CRP) levels, fatigue (visual analog scale [VAS]), physical function (Bath Ankylosing Spondylitis Functional Index [BASFI]) and disease activity were evaluated at baseline and week 24. Anemia was defined as a hemoglobin level <12 gm/dl for women and <13 gm/dl for men.

Results. At baseline, 11 placebo group patients (16.2%) and 37 infliximab group patients (19.7%) had anemia. Of these, more infliximab-treated patients achieved normal hemoglobin levels at week 24 compared with patients receiving placebo (70.3% versus 27.3%; P = 0.0155). Infliximab-treated patients had significant improvements in mean hemoglobin concentration (0.7 gm/dl versus -0.3 gm/dl), BASFI score (-2.1 versus -0.2), and fatigue VAS score (-2.4 versus -0.4) compared with placebo patients (P < 0.001). Multiple regression analyses showed that improvements in hemoglobin level were significantly and independently associated with improvements in physical function and fatigue. Infliximab-treated patients with elevated CRP or IL-6 levels at baseline were more likely than those with low levels to have improvement in hemoglobin levels.

Conclusion. Infliximab treatment significantly decreased the proportion of AS patients with anemia and improved hemoglobin levels compared with placebo. Improvement in hemoglobin level was independently associated with improvements in physical function and fatigue.},
  author       = {Braun, Juergen and van der Heijde, Desiree and Doyle, Mittie and Han, Chenglong and Deodhar, Atul and Inman, Robert and de Vlam, Kurt and Burmester, Gerd and Van den Bosch, Filip and Xu, Stephen and Visvanathan, Sudha and Rahman, Mahboob},
  issn         = {0004-3591},
  journal      = {ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH},
  language     = {eng},
  number       = {8},
  pages        = {1032--1036},
  publisher    = {Wiley-Liss},
  title        = {Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with Infliximab},
  url          = {http://dx.doi.org/10.1002/art.24865},
  volume       = {61},
  year         = {2009},
}

Altmetric
View in Altmetric
Web of Science
Times cited: